.png)
Averitas Pharma, a leader in the US for holistic pain management, was formed in 2018 as the US commercial subsidiary of The Grünenthal Group, a global leader in research and development of therapeutics for pain, gout, and inflammation.
The first innovation from Averitas Pharma in the US is QUTENZA® (capsaicin) 8% topical system, which is a result of acquisitions in 2016 and 2018. These acquisitions give Grünenthal global commercial rights to QUTENZA and provide Averitas with its first FDA-approved product for distribution. QUTENZA is currently marketed and distributed by Averitas Pharma.
M-QZA-US-02-22-0010
February 2022